Physician profile
Laszlo J Makk
NPI 1235135955
$8,990.06
in general payments reported to CMS, 2019-2025
41 companies · $985 in 2025
The $985 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,228 · 2020: $742 · 2021: $1,440 · 2022: $1,485 · 2023: $1,479 · 2024: $1,631 · 2025: $985.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,063 · Education: $32.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,062.62 |
| Education | $32.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,457.02 | 2019-2025 | |
| Janssen Biotech, INC. | $820.43 | 2019-2025 | Stelara, Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $792.54 | 2019-2025 | Trulance, Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $718.23 | 2019-2024 | Entyvio, Eohilia |
| Genzyme Corporation | $295.70 | 2022-2025 | |
| Pfizer INC. | $267.32 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $231.41 | 2024-2025 | Voquezna |
| Celgene Corporation | $226.61 | 2021-2023 | Zeposia |
| Medtronic, INC. | $183.46 | 2022 | |
| Ironwood Pharmaceuticals, INC | $172.25 | 2019-2024 | Linzess |
| Ardelyx, INC. | $171.11 | 2022-2024 | Ibsrela |
| Evoke Pharma, INC. | $169.73 | 2020-2021 | |
| Ucb, INC. | $145.37 | 2019-2021 | |
| Sanofi US Services INC. | $134.33 | 2025 | |
| Intercept Pharmaceuticals, INC. | $125.24 | 2020-2025 | Ocaliva |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $119.97 | 2022-2024 | Dificid |
| Organon LLC | $97.46 | 2022-2024 | Renflexis, Hadlima |
| Lilly USA, LLC | $92.94 | 2023-2025 | Omvoh |
| E.R. Squibb & Sons, L.L.C. | $88.76 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $67.11 | 2022-2025 | Dupixent |
| Gilead Sciences, INC. | $63.43 | 2025 | Livdelzi |
| Qol Medical, LLC | $62.83 | 2021-2024 | Sucraid |
| Fresenius Kabi USA, LLC | $49.95 | 2023-2024 | Idacio |
| Celltrion USA INC. | $39.73 | 2024-2025 | Vegzelma, Zymfentra |
| Redhill Biopharma INC. | $39.68 | 2020-2023 | Talicia, Aemcolo, Movantik |
| Allergan, INC. | $38.48 | 2019-2020 | |
| Daiichi Sankyo INC. | $35.86 | 2021-2024 | Injectafer |
| Amgen INC. | $33.23 | 2022-2023 | Avsola, Amjevita |
| Madrigal Pharmaceuticals | $31.75 | 2025 | Rezdiffra |
| Janssen Scientific Affairs, LLC | $29.47 | 2024 | Stelara |
| Ethicon US, LLC | $28.71 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $20.99 | 2024 | Andexxa |
| Azurity Pharmaceuticals, INC. | $18.22 | 2025 | Sutab |
| Axonics, INC. | $17.47 | 2022 | |
| Braintree Laboratories, INC. | $17.44 | 2024 | Suflave |
| Romark Laboratories, Lc | $16.87 | 2019-2020 | |
| Albireo Pharma, INC. | $14.28 | 2024 | Iqirvo |
| Nestle Healthcare Nutrition INC. | $14.16 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.74 | 2023 | Cyltezo |
| Shionogi INC | $13.62 | 2019 | |
| Amag Pharmaceuticals, INC. | $13.16 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laszlo Makk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.